XNAS · Healthcare · Biotechnology
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-10 | Q2 2026 | -4.84 | -2.58 | +46.69% | $0 | ✅ Beat | +1.83% | +19.42% | +19.16% |
| 2025-12-11 | Q1 2026 | -3.28 | -4.35 | -32.62% | $0 | ❌ Miss | — | — | — |
| 2025-10-16 |
| Q4 2025 |
| -3.28 |
| -4.81 |
| -46.65% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-03-12 | Q2 2025 | — | -2.33 | — | $0 | — | -5.48% | +16.99% | +19.18% |
| 2024-12-16 | Q1 2025 | -4.50 | -3.30 | +26.67% | $0 | ✅ Beat | +6.17% | -13.01% | -34.24% |
| 2024-10-29 | Q4 2024 | -7.80 | -1.05 | +86.54% | $0 | ✅ Beat | -7.50% | -12.83% | +18.03% |
| 2024-06-14 | Q3 2024 | -8.25 | 1.65 | +120.00% | $0 | ✅ Beat | +4.23% | -15.85% | -34.51% |
| 2024-03-18 | Q2 2024 | -3.00 | -10.65 | -255.00% | $0 | ❌ Miss | — | — | — |
Showing last 8 quarters.